CAS No.
[1018899-04-1 (Unlabeled)]
Therapeutic Uses
Anti-Diabetic
Storage Condition
Store at refrigerator (2-8ยฐC) for long term storage
Synonyms
(5S)-Methyl 5-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-thio-ฮฒ-L-xylopyranoside (ACI); (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol
Application Notes
Useful research chemical for a range of applications
Hazard Compound
No -Refer MSDS for accurate information
Sotagliflozin-d3 is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Sotagliflozin-d3 usage and description
Sotagliflozin D3 is a drug that is used to treat type 1 and type 2 diabetes. It works by inhibiting two types of glucose transporters in the body, SGLT1 and SGLT2. SGLT1 is responsible for glucose absorption in the gastrointestinal tract, while SGLT2 is responsible for glucose reabsorption in the kidneys. By inhibiting these transporters, sotagliflozin D3 decreases glucose absorption and increases glucose excretion in the urine, leading to lower blood glucose levels.
Sotagliflozin D3 is typically taken orally in tablet form, with or without food. The dosage and duration of treatment will depend on the individual's medical history, response to treatment, and other factors such as age and weight. It is important to follow the prescribing doctor's instructions carefully to ensure safe and effective treatment.
Chemically, sotagliflozin D3 is a deuterated version of sotagliflozin, a drug that was approved by the FDA in 2019 for use in adults with type 1 diabetes. Deuterium is an isotope of hydrogen that has an extra neutron in its nucleus, making it slightly heavier than regular hydrogen. This modification can enhance the drug's metabolic stability and improve its pharmacokinetic properties, leading to better efficacy and safety. Sotagliflozin D3 is still undergoing clinical trials to determine its effectiveness and safety in treating diabetes.
